CeriBell, Inc. (NASDAQ:CBLL) Given Average Rating of “Buy” by Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received an average recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $32.50.

Several research firms recently issued reports on CBLL. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH assumed coverage on CeriBell in a research note on Friday, April 4th. They issued a “buy” rating and a $32.00 price target for the company.

Insider Transactions at CeriBell

In other news, Director Rebecca B. Robertson sold 20,000 shares of the business’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $17.14, for a total value of $342,800.00. Following the sale, the director now directly owns 28,675 shares in the company, valued at $491,489.50. The trade was a 41.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Xingjuan Chao sold 3,372 shares of the stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $15.03, for a total transaction of $50,681.16. Following the completion of the transaction, the chief executive officer now directly owns 743,079 shares of the company’s stock, valued at approximately $11,168,477.37. The trade was a 0.45% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 94,700 shares of company stock valued at $1,564,234. 20.10% of the stock is currently owned by insiders.

Institutional Trading of CeriBell

A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers bought a new position in CeriBell during the fourth quarter valued at $320,000. Bank of New York Mellon Corp purchased a new position in shares of CeriBell during the 4th quarter worth about $628,000. Charles Schwab Investment Management Inc. bought a new position in CeriBell during the 4th quarter valued at about $2,500,000. PNC Financial Services Group Inc. purchased a new stake in CeriBell in the 4th quarter worth about $47,000. Finally, Vanguard Group Inc. bought a new stake in CeriBell in the fourth quarter worth about $18,015,000.

CeriBell Stock Performance

Shares of NASDAQ:CBLL opened at $17.74 on Wednesday. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The firm’s 50 day simple moving average is $16.51 and its two-hundred day simple moving average is $20.92. The company has a quick ratio of 16.81, a current ratio of 17.36 and a debt-to-equity ratio of 0.11.

CeriBell (NASDAQ:CBLL) last released its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to analysts’ expectations of $19.30 million. On average, research analysts anticipate that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.